Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults

PLoS Neglected Tropical Diseases

Volumn 8, Issue 5, 2014, Pages

  Altcheh, Jaime ^a   Moscatelli, Guillermo ^a   Mastrantonio, Guido ^b   Moroni, Samanta ^a   Giglio, Norberto ^a   Marson, Maria Elena ^b   Ballering, Griselda ^a   Bisio, Margarita ^a   Koren, Gideon ^c   García Bournissen, Facundo ^a,c  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; CHAGAS DISEASE; CHILD; CLEARANCE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFICACY; DRUG ELIMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SIMULATION; BLOOD; CLINICAL TRIAL; METABOLISM; STATISTICAL MODEL;

ADULT; CHAGAS DISEASE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LINEAR MODELS; MALE; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS;

EID: 84901788390     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002907     Document Type: Article

References (36)

1. Teixeira A R, Nascimento R J, Sturm N R, (2006) Evolution and pathology in chagas disease-a review. Mem.Inst.Oswaldo Cruz 101: 463-491.
2. Tarleton R L, Reithinger R, Urbina J A, Kitron U, Gurtler R E, (2007) The challenges of Chagas Disease- grim outlook or glimmer of hope. PLoS.Med 4: e332.
3. Schmunis G A, Yadon Z E, (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 14-21.
4. Yadon Z E, Schmunis G A, (2009) Congenital Chagas disease: estimating the potential risk in the United States. Am.J.Trop.Med.Hyg 81: 927-933.
5. Schmunis G. A. (10-30-2007) Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem.Inst.Oswaldo Cruz 102Suppl 1: 75-85.
6. Moscatelli G, Garcia Bournissen F, Freilij H, Berenstein A, Tarlovsky A, et al. (2013) Impact of migration on the occurrence of new cases of Chagas disease in Buenos Aires city, Argentina. J Infect.Dev.Ctries 7: 635-637.
7. Machado F S, Tanowitz H B, Teixeira M M, (2010) New drugs for neglected infectious diseases: Chagas' disease. Br.J.Pharmacol 160: 258-259.
8. Jannin J., Villa L. (10-30-2007) An overview of Chagas disease treatment. Mem.Inst.Oswaldo Cruz 102Suppl 1: 95-97.
9. Garcia-Bournissen F, Altcheh J, Giglio N, Mastrantonio G, Della Vedova C O, et al. (2009) Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Paediatr.Drugs 11: 33-37.
10. Sosa Estani S, Segura E L, Ruiz A M, Velazquez E, Porcel B M, et al. (1998) Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am.J.Trop.Med.Hyg 59: 526-529.
11. de Andrade A L, Zicker F, de Oliveira R M, Almeida Silva S, Luquetti A, et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
12. Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H, (2005) [Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina]. Rev.Soc.Bras.Med.Trop 38Suppl 2: 41-45.
13. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H, (2011) Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 127: e212-e218.
14. Raaflaub J, Ziegler W H, (1979) Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 29: 1611-1614.
15. Raaflaub J, (1980) Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 30: 2192-2194.
16. Garcia-Bournissen F, Altcheh J, (2011) Antitrypanosomal therapy for chronic Chagas' disease. N.Engl.J.Med 365: 1258.
17. Piron M, Fisa R, Casamitjana N, Lopez-Chejade P, Puig L, et al. (2007) Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop 103: 195-200.
18. Duffy T, Bisio M, Altcheh J, Burgos J M, Diez M, et al. (2009) Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS.Negl.Trop.Dis 3: e419.
19. Duffy T, Cura C I, Ramirez J C, Abate T, Cayo N M, et al. (2013) Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS.Negl.Trop.Dis 7: e2000.
20. WHO Expert Committee on the Control of Chagas Disease, World Health Organization (2002) Control of Chagas disease: second report of the WHO Expert Committee on Chagas Disease.
21. Freilij H, Altcheh J, (1995) Congenital Chagas' disease: diagnostic and clinical aspects. Clin.Infect.Dis 21: 551-555.
22. Marson M E, Padro J M, Reta M R, Altcheh J, Garcia-Bournissen F, et al. (2013) A simple and efficient HPLC method for benznidazole dosage in human breast milk. Ther.Drug Monit 35: 522-526.
23. Marson M E, Dana D D, Altcheh J, Garcia-Bournissen F, Mastrantonio G, (2013) Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies. J Clin Lab Anal 27: 384-390.
24. Jonsson E N, Karlsson M O, (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput.Methods Programs Biomed 58: 51-64.
25. Barry M A, Weatherhead J E, Hotez P J, Woc-Colburn L, (2013) Childhood parasitic infections endemic to the United States. Pediatr Clin North Am 60: 471-485.
26. Moolani Y., Bukhman G., Hotez P J. (2012) Neglected tropical diseases as hidden causes of cardiovascular disease. PLoS.Negl.Trop.Dis. 6: e1499-.
27. Sosa-Estani S, Segura E L, (2006) Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr.Opin.Infect.Dis 19: 583-587.
28. Sosa Estani S, Segura E L, (1999) Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem.Inst.Oswaldo Cruz 94Suppl 1: 363-365.
29. WHO Expert Committee on the Control of Chagas Disease, World Health Organization (2005) Report of the WHO Expert Committee on the Control of Chagas Disease, 2005.905:.
30. Anderson B J, Allegaert K, Holford N H, (2006) Population clinical pharmacology of children: general principles. Eur.J.Pediatr 165: 741-746.
31. Anderson B J, Allegaert K, Holford N H, (2006) Population clinical pharmacology of children: modelling covariate effects. Eur.J.Pediatr 165: 819-829.
32. Viotti R, Vigliano C, Lococo B, Alvarez M G, Petti M, et al. (2009) Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert.Rev.Anti.Infect.Ther 7: 157-163.
33. Viotti R, Vigliano C, (2007) Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert.Rev.Anti.Infect.Ther 5: 717-726.
34. Workman P, White R A, Walton M I, Owen L N, Twentyman P R, (1984) Preclinical pharmacokinetics of benznidazole. Br.J.Cancer 50: 291-303.
35. Marin-Neto J A, Rassi A Jr, Morillo C A, Avezum A, Connolly S J, et al. (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am.Heart J. 156: 37-43.
36. Pinazo M J, Guerrero L, Posada E, Rodriguez E, Soy D, et al. (2013) Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob.Agents Chemother 57: 390-395.